This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Related articles  • Similar articles in this journal  Topic Collections  • Metabolic Diseases  • Cardiovascular Disease/ Myocardial Infarction  • Alert me on articles by topic

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

In a recent subset analysis of the Bezafibrate Infarction Prevention (BIP) trial, investigators looked at the effects of bezafibrate on patients with metabolic syndrome (MS).¹ Tenenbaum et al¹ reached the conclusions that "bezafibrate reduces the incidence of MI [myocardial infarction] in patients with metabolic syndrome during long-term follow-up,"^1(p1154) that bezafibrate was "safe and effective in the secondary prevention of MI in patients with MS,"^1(p1159) and that there was a "trend to a 26% reduction of cardiac mortality rate."^1(p1156) They also stated that in patients with augmented features of MS (4-5 risk factors), "the remarkable strengthening of cardiac mortality reduction when taking bezafibrate . . . should be noted."^1(p1154)

Cross-referencing the data of Tenenbaum et al¹ with the originally published BIP study data,² we performed a similar subset analysis of the patients without MS (based on the authors’ criteria) and give the results in the Table.

Table appears in full text version. Table. Deaths in Patients With Less Than 3 . . . [Full Text of this Article]

AUTHOR INFORMATION
James McCormack, BSc(Pharm), ACPR, PharmD; Peter Loewen, BSc(Pharm), ACPR, PharmD, FCSHP

RELATED ARTICLES

The Other Side of the Bezafibrate Infarction Prevention Trial Data—Reply
Alexander Tenenbaum, Michael Motro, Enrique Z. Fisman, David Tanne, Valentina Boyko, and Solomon Behar
Arch Intern Med. 2005;165(20):2432.
EXTRACT | FULL TEXT  

Bezafibrate for the Secondary Prevention of Myocardial Infarction in Patients With Metabolic Syndrome
Alexander Tenenbaum, Michael Motro, Enrique Z. Fisman, David Tanne, Valentina Boyko, and Solomon Behar
Arch Intern Med. 2005;165(10):1154-1160.
ABSTRACT | FULL TEXT